FDA issues priority review voucher for ZANVASTRO
FDA approved ZANVASTRO on September 3, 2026. FDA issued a priority review voucher to the sponsor, Ionis Pharmaceuticals, Inc., after determining the product meets the criteria under the FD&C Act.
Primary source
Federal Register notice, October 9, 2026
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZANVASTRO (Zilganersen)
Read the source: Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZANVASTRO (Zilganersen) federalregister.gov
Machine-summarized from the source above; not independently reported. How we use automation